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ABSTRACT
Numerous Helicobacter pylori virulence factors, including various enzymes (urease, catalase, lipase,
phospholipase and proteases), vacuolating cytotoxin (a product of expression of the vacA gene), and the
immunogenic protein CagA, encoded by the cagA gene localised in the H. pylori pathogenicity island, are
involved in the pathomechanism of infection caused by these organisms. This review presents the
current state of knowledge concerning the molecular mechanisms and epidemiology of H. pylori
infection, based on the published literature and recent unpublished observations.
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INTRODUCTION
Helicobacter pylori was first described in 1983 [1]
as ‘unidentified curved bacilli on gastric epithe-
lium in active chronic gastritis’ in 50% of
patients attending at the Royal Hospital, Perth,
Western Australia for gastroscopy and biopsy.
These unidentified bacterial cells were difficult
to visualise with haematoxylin and eosin stain,
but were stained easily by the Warthin–Starry
silver stain method. Even in 1983, when little
was known regarding the pathology of H. pylori,
Warren [1] connected these bacteria with a
specific type of inflammation in the stomach.
Gastric biopsy findings were classified accord-
ing to the type of inflammation, i.e., no inflam-
mation, chronic gastritis, and active chronic
gastritis. When there was no inflammation,
bacteria were observed rarely. Bacteria were
often found in chronic gastritis, but were rarely
numerous. However, the curved bacilli were
almost always present in active chronic gastritis,
often in large numbers, and often growing
between the cells of the surface epithelium. It
was concluded that the curved bacilli, and the
associated histological changes, may be present
in any part of the stomach, but that they were
seen most consistently in gastric antrum. In a
companion report by Marshall [1], the morphol-
ogy and environmental requirements of these
curved bacteria were described. The author
mentioned that ‘in other mammals (especially
monkeys), spiral gastric bacteria are well-known
and are thought to be commensals’, and con-
cluded that the unknown bacteria might belong
to the genus Spirillum. More detailed informa-
tion regarding these novel bacteria was pub-
lished in 1984, and the authors commented that
‘‘if it is premature to talk of ‘Campylobacter
pyloridis’ perhaps the name ‘pyloric campylo-
bacter’ will do to define the site where these
organisms are commonly found and to indicate
the similarity to known Campylobacter spp.’’ [2].
Today, H. pylori is recognised as an established
causative agent of chronic inflammation of the
mucous membranes of the stomach and of peptic
ulcer. Moreover, infection with H. pylori is one of
the risk-factors for gastric neoplasms, including
lymphomas and gastric cancer [3]. In 1994, the
WHO classified H. pylori as a class 1 carcinogen.
The prevalence of H. pylori infection varies
widely according to geographical area, patient
age and socio-economic status. Rates of isolation
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appear to be higher in developing countries (70–
90%) than in developed countries (25–50%) [4].
The prevalence of infection is higher in older age
groups than in younger age groups. There is no
documented association between alcohol and
nicotine use and H. pylori infection. Individuals
with higher education have considerably lower
levels of infection when compared with indivi-
duals with only primary or secondary education
[4]. The principal reservoir of H. pylori is man,
but there have been descriptions of infection
spread by means of water or uncooked vegetables
contaminated with sewage [5]. The role of domes-
tic animals in the spread of H. pylori infection is
not yet proven, and, in general, infection is
probably passed directly from individual to indi-
vidual. Proposed routes of transmission of
H. pylori are faecal–oral, oral–oral, and gastric–
oral [5].
Studies of polymorphic DNA sequences in
H. pylori have suggested geographical origins for
particular individual strains. In North America, a
180-bp insertion (ins180) has been described [6],
which was found in 56% of isolates from African-
Americans, but in only 17% of isolates from
Caucasian-Americans. It was concluded that
H. pylori strains found in modern African-Amer-
icans seem to retain traces of their African roots,
despite the multiple generations since their ances-
tors were taken from West Africa. Apparent
differences between African-American and Cau-
casian-American H. pylori gene pools may con-
tribute to an understanding of H. pylori
transmission and disease outcome.
H. pylori is usually connected with gastroduo-
denal pathologies. However, the occurrence of
this bacterium in extraduodenal pathologies is
also well-known. In Iran, H. pylori has been found
in patients with gall-bladder disease, suggesting a
possible role for these bacteria in gallstone for-
mation [7]. Another study has reported a poten-
tial association between recurrent aphthous
stomatitis and H. pylori [8]. Infection by H. pylori
is often asymptomatic, but c. 10% of infected
individuals have a peptic ulcer, and some have
gastric cancer (both the intestinal type and the
spreading type). The outcome of infection
depends on the precise infecting bacterial strain
(and especially the large variety of bacterial
virulence factors) and various host factors (gen-
etic predisposition, immune response to infection,
and diet).
VIRULENCE FACTORS OF H. PYLORI
Many virulence factors are involved in the path-
omechanism of infection caused by H. pylori,
including various enzymes (e.g., urease, catalase,
lipase, phospholipase and proteases) produced
by all described strains of H. pylori, and toxins,
such as vacuolating cytotoxin, encoded by the
vacA gene, and the immunogenic protein CagA,
encoded by the cagA gene (cytotoxin-associated
gene), which is localised in the H. pylori patho-
genicity island (PAI). The PAI also contains a
number of other genes responsible for virulence,
expression of pro-inflammatory cytokines (mostly
interleukin-8 (IL-8)) in epithelial cells, and expres-
sion of proteins forming a type 4 secretion system
(T4SS) for transport of CagA protein to eukaryotic
cells [9].
Urease is the most important enzyme produced
by H. pylori, since it enables survival of the
organism in a low-pH environment, and also aids
colonisation of the stomach mucous membrane.
The enzyme catalyses the degradation of urea to
ammonia and carbon dioxide. Ammonia alkalises
the environment, leading to neutralisation of the
acid fluid in the stomach, which allows bacterial
survival. Urease was the first virulence factor of
H. pylori used for diagnostic purposes in gastric
pathology.
Initially, the vacuolisation activity of H. pylori
culture supernatants was attributed to urease
activity rather than to a specific cytotoxin [10].
The degradation of 5 mM urea (the maximal
concentration found in gastric fluid) by urease
liberates ammonia, which is reported to induce
cell injury [11], and has long been known to
induce cell vacuolisation. However, Cover et al.
[12] used supernatants from urease-positive and
urease-negative strains to demonstrate that cell
vacuolisation did not depend on the presence of
urease activity in H. pylori. In addition, it was
shown that supernatants with and without vacu-
olating activity did not differ significantly in
urease activity. It was concluded that putative
toxin and ammonia generated by H. pylori urease
activity may contribute to cell vacuolisation in an
additive fashion.
More recent studies have concentrated on
the mechanisms involved in regulating urease
activity and on localising the genes involved. At
least seven genes are involved in the production
of urease. The ureAB genes encode two units of
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the enzyme, while the ureEFGH genes encode the
accessory proteins responsible for incorporating
nickel in the active centre of the enzyme, and ureI
encodes the protein responsible for transport of
urea. Subsequent studies of ureI revealed that it
functions as a channel in the outer-membrane, by
means of which urea is transported into the target
cell. A decreased pH in the environment induces
the activity of this gene [13,14]. The two enzymes
phospholipase A and C are responsible for
destruction of the protective mucous zone, and
these two enzymes are present in all strains of
H. pylori [3].
Other very important virulence factors are
adhesins, which allow binding of bacteria to the
gastric cells. Many different molecules show
adhesion activity, including the BabA2 outer-
membrane protein, which is encoded by the bab
(blood group antigen binding) genes. BabA2
protein can bind fucosylated polysaccharides,
which are blood antigens known as Lewis blood
antigens [15,16]. These antigens have been found
both on the surface of mucous membrane and in
H. pylori lipopolysaccharide. Mimicry between
H. pylori lipopolysaccharide and Lewis blood
antigens of the host could be responsible for the
autoimmunisation that occurs during gastritis
[17].
Production of cytotoxin and the presence of the
PAI are thought to be the main virulence factors
of H. pylori. Not all strains are able to produce
cytotoxin and CagA protein, but those strains
with the ability to do so seem to be more virulent.
Such strains are involved in the process of
ulcerogenesis. Currently, research is underway
to determine the mechanism of carcinogenesis
and to characterise the factors responsible for this
process. These studies involve investigations of
the expression of host genes, including oncogenes
and suppressor genes of the neoplasmic process,
the influence of H. pylori on apoptosis and the
proliferation of gastric epithelial cells, and the
influence of bacterial virulence factors on the cells
of the lymphatic system, including B- and
T-lymphocytes, and macrophages.
H. pylori causes a variety of pathological chan-
ges and clinical outcomes, including gastric can-
cer and duodenal ulcers. Infected individuals
with gastritis localised mostly in the antrum of
the stomach retain normal (or high) acid secre-
tion, while individuals with extensive corpus
gastritis develop hypochlorhydria and gastric
atrophy, which are presumptive precursors of
gastric cancer [18]. Some individuals with inflam-
mation of the antrum of the stomach may show
atrophy of the mucous membrane, with develop-
ment of intestinal metaplasia, dysplasia and
gastric cancer (intestinal type). The development
of hypochlorhydria, and even achlorhydria, may
also be a risk factor for carcinogenesis [19].
VACUOLATING CYTOTOXIN (VacA)
VacA was first discovered in 1988 in the supern-
atants of 50% of H. pylori cultures [20]. This
protein induced the in-vitro creation of vacuoles
in many different cell lines. The VacA cytotoxin
belongs to the AB group of toxins, which are
made up of an A-subunit, responsible for enzymic
activity, and a B-subunit, responsible for recog-
nising and binding to receptors on the surface of
target cells. The production of VacA cytotoxin has
been linked to the in-vivo destruction of epithelial
cells and the development of peptic ulcer in
Mongolian gerbils infected with H. pylori [21].
Subsequent studies have demonstrated that
VacA is synthesised as a 140-kDa pro-toxin,
which undergoes cleavage of both an N-terminal
signal sequence and a C-terminal domain to yield
a mature secreted toxin of c. 90 kDa. These c. 90-
kDa VacA monomers then oligomerise to form
complex six- or seven-sided flower-like struc-
tures, c. 12 nm in height and 30 nm in diameter.
When exposed to acidic pH, the VacA oligomers
disassemble into monomeric components, and
this disassembly is accompanied by a marked
increase in vacuolating activity [22]. In 1999,
Reyrat et al. [23] demonstrated that the cytotoxin
undergoes proteolytic cleavage into two frag-
ments, a 37-kDa N-terminal fragment and a
58-kDa C-terminal fragment, which are non-cov-
alently associated. After the 58-kDa B-subunit
binds to the receptor, the A-subunit is internal-
ised, which results in vacuolation.
Yahiro et al. [24] demonstrated that H. pylori
VacA binds to the 140-kDa protein present in
human gastric cell lines. Later, Massari et al. [25]
showed that this protein is a specific and satura-
ble receptor for VacA, and that the biological
activity of VacA is mediated through this high-
affinity cell surface receptor. The same authors
also demonstrated that VacA binds to different
epithelial human and mouse cell lines with a
similar affinity, indicating that the structure of the
604 Clinical Microbiology and Infection, Volume 11 Number 8, August 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 602–610
receptor is also conserved in other species. How-
ever, the presence of this receptor is not ubiquit-
ous, and some cell lines lack susceptibility to
VacA cytotoxin [26]. Pessina et al. [26] demon-
strated that HaCaT (human keratinocytes) and
HeLa (human cervix carcinoma) cells showed a
similar sensitivity, but that gastric HGC-27
(human gastric cancer) cells appeared to be
significantly resistant to VacA activity. These
experiments used two H. pylori broth culture
filtrates derived from different genotypes (VacA+
and VacA–). Although the VacA– filtrate did not
produce vacuolisation, it affected cell prolifer-
ation and was cytotoxic for all cell lines studied.
The results were confirmed in anti-clonogenic
assays with HeLa cells, and it was concluded that
the anti-proliferative activity of the VacA– filtrate
could be related to the presence in the filtrate of
an unknown factor produced by H. pylori; how-
ever, given the large difference in sensitivity
found between the different cell lines with the
VacA– filtrate, some possible specific activity
could not be excluded. Ricci et al. [27] demonstra-
ted that endocytosis of VacA channels does not
occur via the clathrin-coated pit pathway, but via
an actin-dependent caveole-like internalisation
pathway. This was confirmed by the absence of
inhibition of VacA binding to the lipid rafts, and
by blocking of the internalisation of VacA and
vacuole formation after treatment with cytochala-
sin D, which disrupts the actin cytoskeleton [28].
Vacuoles created by VacA are a mixed prod-
uct of late endosomes and lysosomes with
endosomal rab7 and lysosomal Lgp100 markers.
The process of vacuole creation requires many
cooperating molecules, including rab7 (a low
molecular mass G protein that binds the GTP
responsible for the formation of vacuoles),
RAC1 (a rho family GTPase connected with
pinocytic activity), dynamine (a high molecular
mass G protein involved in the early stages of
vesicle creation), and V-ATPase [23]. It has been
shown that membrane fusion, which takes place
during the transition from the small late endo-
somal compartments to the large vacuoles, is
not dependent on soluble N-ethylmaleimide-
sensitive factor attachment protein receptor
(SNARE) proteins [29]. Papini et al. [30] indica-
ted that a transmembrane pH gradient is
necessary for the formation and growth of
vacuoles caused by H. pylori, and that this pH
gradient is caused by the activity of a vacuolar
ATPase proton pump in HeLa cells. Vacuole
formation is accompanied by a redistribution of
lysosomal membrane glycoproteins among the
endocytic compartments. Bafilomycin A1, a spe-
cific inhibitor of the vacuolar type H+-ATPase,
at a concentration of 4 nM, prevents vacuoli-
sation of HeLa cells by H. pylori. Moreover,
bafilomycin A1 was very efficient in restoring
the normal appearance of cells vacuolated as a
result of H. pylori activity [30].
Although c. 50% of H. pylori strains are non-
toxigenic, all strains possess the gene (vacA) that
encodes the vacuolating cytotoxin. The first 25
amino-acids of the VacA protein sequence are
highly conserved, but the remainder of the signal
sequence in non-toxigenic strains differs consid-
erably from the corresponding region in toxigenic
strains. Alignment of the vacA nucleotide
sequences of toxigenic and non-toxigenic H. pylori
strains has revealed two distinct families, namely
s1 (s1a; s1b) and s2, with one of two different vacA
alleles in the middle region (m1 and m2). Analysis
of different isolates of H. pylori has revealed all
possible combinations of these alleles, with the
exception of s2 ⁄m1, suggesting that recombina-
tion events occur in nature between different vacA
alleles [31]. It has been reported that a high level
of activity correlates with the vacA s1 ⁄m1 geno-
type, while the vacA s1 ⁄m2 genotype correlates
with low activity [32]. There was no activity in
strains with the vacA s2 ⁄m2 genotype. It has also
been demonstrated that H. pylori strains with the
s1a genotype are responsible for more severe
inflammatory reactions [33].
In regions where the background rate of distal
gastric cancer is high, such as Colombia and
Japan, most H. pylori strains carry s1 ⁄m1 alleles
[34–36]. The clinical outcome of H. pylori infection
is thought to be linked to the production of VacA
cytotoxin and the presence of the cytotoxin-
associated gene (cagA), which is located in the
cag PAI. This is a region of DNA (c. 40 kb) that
contains the cagA gene, encoding the highly
immunogenic protein CagA, and several other
genes connected with pathogenicity. It has been
demonstrated that the vacA s1 genotype correlates
with the presence of the cagA gene [32], and
that vacA ⁄ s1 ⁄ cagA strains are the most viru-
lent. These strains are isolated more frequently
from the samples of patients with peptic ulcer
than are strains belonging to other genotypes
[32,33,37,38].
Radosz-Komoniewska et al. Pathogenicity of H. pylori infection 605
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 602–610
Most H. pylori cells are located outside of
gastric cells, and only 1–10% are localised inside
these cells. Living and moving bacteria have been
found inside vacuoles, and Petersen et al. [39]
found that H. pylori vacuolating cytotoxin may be
involved in the intracellular survival of the
bacterium. H. pylori may be localised in compart-
ments built from early endosomes, thereby avoid-
ing fusion with lysosomes, because of host
tryptophan ⁄ aspartate-containing coat (TACO)
protein, which makes it impossible to create
phagolysosomes [40]. Intracellular localisation
might protect H. pylori from antibiotics and
macrophages.
As H. pylori is found only rarely in the deeper
portion of the gastric mucosa, where O-gly-
cans are expressed with terminal a-1,4-linked
N-acetylglucosamine, Kawakubo et al. [41] stud-
ied whether this was a host defence mechanism
against this bacterium. It was demonstrated that
O-glycans have antimicrobial activity against
H. pylori, inhibiting biosynthesis of cholesteryl-
a-D-glycopyranoside, a major bacterial cell wall
component. It was concluded that the unique
O-glycans in gastric mucin function as a natural
antibiotic, thereby protecting the host from
H. pylori. Another Japanese group demonstrated
in 2005 [42] that glycopolypeptides from butter-
milk promote the exfoliation of H. pylori bound
to gastric mucin, and prevent the de-novo
adherence of this bacterium. It was concluded
that glycopolypeptides are a promising food
material for preventing H. pylori infection.
Spontaneous elimination of H. pylori infection
has been described in children [43], but further
investigations are needed to understand this
phenomenon.
VacA AND APOPTOSIS
It has been established that infection with H. pylori
can lead to an imbalance between proliferation
and apoptosis, which can result in severe clinical
consequences, and even lead to gastric cancer
[44,45]. H. pylori can both increase and decrease
the level of apoptosis. Numerous H. pylori viru-
lence factors (e.g., urease, VacA and CagA) may
influence apoptosis [46–48]. Galmiche et al. [47]
found that cytotoxin can induce apoptosis, via the
mitochondria-dependent pathway, by activating
caspase-3. This was suggested from observations
of the early effects on HeLa cells incubated
with VacA, namely the release of cytochrome c
from the inter-membrane space of mitochondria.
VacA channel-forming activity is important for
cytochrome c release, and this release is inhibited
by channel inhibitors known to block VacA
channel activity, and also by cellular vacuolisa-
tion [49]. Consequently, it has been hypothesised
that cytochrome c release could lead to vacuoli-
sation, being a downstream stress response. This
hypothesis was supported by the fact that a
mutant VacA toxin lacking vacuolating activity
failed to induce apoptosis [45]. However, it has
been found that vacuole biogenesis occurs much
earlier than cytochrome c release, and that VacA
concentrations unable to induce cytochrome c
release are still high enough to cause vacuolisa-
tion [50].
Apoptosis in gastric epithelial cells in vivo
results from toxin VacA activity, and also from
many other factors, which remain in inflamed
gastric mucous membrane. Pro-inflammatory
cytokines, IL-1b, interferon-c, tumour necrosis
factor-a, FasL and nitric oxide produced by
neutrophils and macrophages, as well as indu-
cible nitric oxide synthase, can be responsible
for high levels of apoptosis. Increased apoptosis
appears to be one of the first stages in carcin-
ogenesis, leading to atrophy, which is thought
to be an important risk-factor for gastric cancer.
Increased expression of inducible nitric oxide
synthase has been found in the stomach mucus
of individuals with stomach cancer [51–53].
However, low levels of apoptosis have also
been found in individuals with stomach cancer
and in individuals with intestinal metaplasia. The
results of these studies indicate improper expres-
sion of the genes responsible for apoptosis,
i.e., bak, bax (pro-apoptotic) and bcl-2 (inhibitor
of apoptosis) [54]. According to Konturek et al.
[55], decreased expression of the bak and bax
genes, but increased expression of the bcl-2 gene,
can be found in individuals with stomach cancer.
Apoptosis as a result of the activity of the VacA
toxin, and other virulence factors produced by
H. pylori, could be an important factor in influen-
cing the pathogenesis of stomach cancer. The
precise mechanisms involved are not yet known,
but an increased number of dead epithelial cells
can lead to atrophy of mucous membrane and to
metaplasia. Apoptosis can also result in hyper-
proliferation, which could be an important factor
in the evolution of stomach cancer.
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VacA, cagA AND PATHOGENICITY
ISLAND
An association between infection with cagA-posit-
ive H. pylori strains, the risk of peptic ulcer disease,
and the development of atrophic gastritis and
carcinoma of the stomach, has been described
[56,57]. Figuieredo et al. [57] reported that com-
bined bacterial–host genotyping may provide an
important tool for defining the risk of disease.
Human genetic polymorphism appears to play
a role in the susceptibility of the host. Thus,
polymorphism of the IL-1b gene and the IL-1
receptor antagonist gene (IL-1RN) has been asso-
ciated with an increased risk of both hypochlorhy-
dria and gastric carcinoma. A polymorphism allele
with a ‘T’ instead of a ‘C’ at position 511 of the IL-1b
regulatory region (IL-1b-511T*) is associated with
increased IL-1b production. The IL-1RN has a
variable number of tandem repeats in intron 2,
resulting in a short allele (IL-1RN*2 with two
repeats) or a long allele (IL-1RN*L with between
three and six repeats). IL-1RN*2 is associated with
increased IL-1b production; therefore, H. pylori
infection in individuals with these alleles may
result in the augmentation of gastric atrophy and
hypochlorhydria, leading ultimately to the devel-
opment of gastric carcinoma.
Thus, in addition to its well-known vacuolating
activity, VacA has been reported to induce apop-
tosis in epithelial cells, affect B-lymphocyte anti-
gen presentation, inhibit the activation and
proliferation of T-lymphocytes, and modulate
T-cell-mediated cytokine responses [58]. Vacuo-
lating cytotoxin (VacA) and cytotoxin-associated
antigen A (CagA) are two major bacterial viru-
lence factors involved in host-cell modulation.
VacA, previously regarded mainly as a cytotoxin
of the gastric epithelial cell layer, now appears to
be a potent immunomodulatory toxin, targeting
the adapted immune system.
Various experiments aimed at explaining the
influence of VacA on the immune system have
been performed. Cytotoxin is able to penetrate
epithelial cells, and this process can be facilitated
by opening tight junctions between gastric
epithelial cells, possibly as a result of the action
of VacA and CagA [59]. The toxin can then move
to the sub-epithelial zone, where contact occurs
with polymorphonuclear leukocytes, macropha-
ges, dendritic cells and B- and T-lymphocytes.
Molinari et al. [60] reported that VacA can disrupt
the process of presentation of antigens to CD4
lymphocytes. It has also been shown that toxin
can inhibit proliferation of T-lymphocytes by
inhibiting secretion of IL-2 during transcription
[61]. Many factors are responsible for the activa-
tion of the IL-2 promoter, but VacA cytotoxin
can inhibit intranuclear translocation of NFAT
(nuclear factor of activated T-cells). Gebert
et al. [61] have suggested that calcineurin (serine
phosphatase) is a target for VacA, and that
calcineurin is responsible for the intracellular
location of NFAT, which in turn regulates the
expression of IL-2.
As described above, the cag PAI is a c. 40-kb
region of DNA containing the cagA gene, enco-
ding the highly immunogenic CagA protein, as
well as several other genes connected with patho-
genicity. In most H. pylori strains, the cag PAI is a
continuous sequence, but it can be divided by an
insertion sequence, IS605, into two regions termed
cagI and cagII [9]. The 120-kDa CagA protein is
strongly immunogenic, and CagA-specific anti-
bodies have been found in all individuals suffer-
ing from duodenal cancer, as well as in 73% of
individuals with chronic inflammation of the
gastric mucous membrane [62,63]. The precise
role of the CagA protein has not yet been clarified,
but the cagA gene itself is thought to be an
important virulence marker. Initially, it was
thought that CagA is responsible for stimulating
production of IL-8 by the cells of the mucous
membrane. IL-8 is responsible for the chemotaxis
of inflammatory cells, mostly neutrophils.
According to Fischer et al. [64], 14 of 27 genes in
the PAI must be activated in order to induce
transcription of IL-8. Products of these genes
activate transcription factor NFjB, which is trans-
located to the nucleus and activates transcription
of genes such as IL-8 [65]. CagA is transported to
eukaryotic cells by means of a T4SS, which also
results from the activation of 14 PAI genes [64],
but the precise mechanism and structural basis
for type IV secretion has not yet been elucidated.
Two different mechanisms of H. pylori invasion
have been described [66]. The first is characterised
by the engulfment of lengthwise adherent bac-
teria by finger-like microspikes, and is observed
only in bacteria carrying the complete cag PAI.
Alternatively, the tip of the bacterium invades the
cell via a zipper-like mechanism, which is inde-
pendent of the cag PAI. The production of straight
surface filaments of different lengths, connecting
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the bacteria tightly with the epithelial cell surface,
has also been described.
Novel filamentous surface organelles forming
the T4SS of H. pylori were first observed by
electron-microscopy in 2003 by Rohde et al. [66].
The organelle is often located at one bacterial
pole, but can also be induced by cell contact along
the lateral side of the bacterial cell. It consists of a
rigid ‘needle’, with a diameter of c. 45 nm,
covered focally or completely by a layer of
VirB10-homologous protein HP0527, which enlar-
ges the diameter to 70 nm. VirB7-homologous
protein HP0532 is found at the base of this
organelle. From the confocal microscopy data, it
was concluded that HP0532 is localised close to,
or in, the outer-membrane, whereas HP0527
forms a structure that is anchored in the outer-
membrane surface, but which occasionally
extends from the bacterial surface. The postulated
functions of HP0527 are: mechanical stabilisation
of the whole structure; binding to epithelial cells;
protection of filaments from an acidic environ-
ment; and provision of antigen variety. Rohde
et al. [66] found that the structure of the filament
changed after contact with epithelial cells. There
was also a change in the proteins covering the
needle-like structure, as HP0527 protein covered
the filament completely from the base to the top,
joining the outer-membrane of the bacteria and
that of the host epithelial cell [66]. However, the
mechanism by which CagA is translocated to the
host epithelial cell remains to be clarified. Two
mechanisms have been postulated, namely injec-
tion through the central channel of the filament,
or movement outside the needle towards the cell
[66]. The T4SS could be responsible for opening
tight junctions between the epithelial cells of the
stomach, thereby letting cytotoxin penetrate the
deeper zones of the mucous membrane, where
it can cooperate with the cells of the immune
system.
Pessina et al. [26] hypothesised that H. pylori
products, other than those that have anti-prolif-
erative and toxic activity, may interfere with
different components (such as cytokines) of the
gastric tissue that have a role in the genesis of
diseases associated with this bacterium. These
authors suggested that H. pylori products may
also modulate the sensitivity of cells to drugs
in vitro. Wang et al. [67] suggested that H. pylori is
killed and lysed by acetylsalicylic acid (ASA) at a
concentration of 400 mg ⁄L, while Pessina et al.
[26] found that the inhibitory concentration (IC50)
of ASA for gastric cells was 347 mg ⁄L. It was
concluded that ASA could damage gastric cells
before acting upon bacteria, but the possibility
was also raised that products released following
bacterial killing by ASA could contribute to the
detoxification of drug activity. The phenomenon
of detoxification could be explained merely by
decreased drug biovailability, caused by the
binding of drug to the proteins present in H. pylori
filtrates, although this explanation would not
account for the different levels of detoxification
observed for ciprofloxacin, camptothecin, indo-
methacin and ASA. In addition, this explanation
is not consistent with the significant increase in
ciprofloxacin uptake that VacA+ and VacA–
strains produced in HGC-27 cells, even though
ciprofloxacin is recognised to have a very high
protein-binding capacity (c. 80%). According to
Pessina et al. [26], both filtrates caused detoxifica-
tion of camptothecin, ASA and, partially, indo-
methacin in two cell lines (HeLa and HGC-27).
Most recently, a very interesting study linked
the development of gastric cancer associated with
H. pylori to a mycotoxin called sterigmatocystin
[68]. Sterigmatocystin is a precursor of aflatoxin,
which is produced by Aspergillus versicolor. In
Japan, such fungi are found ubiquitously in the
environment as contaminants in human and
animal foods. It was observed that sterigmatocys-
tin enhanced the development of intestinal me-
taplasia and pre-cancerous lesions of gastric
mucosa in Mongolian gerbils infected with
H. pylori. The accumulation of p53 nucleotide
substitutions in the animals infected with H. pylori
increased in parallel with the increase in gastric
atrophy, while no mutations were noted in the
control group of uninfected animals.
CONCLUSION
The data presented in this review demonstrate
the importance of the interactions between the
virulence factors of H. pylori and the host cells,
and the many different consequences that can
be expected as a result of the interplay between
this bacterium and the cells of the immune
system. However, many questions remain
unanswered and further research is required to
gain a more detailed understanding of the
molecular pathomechanisms of H. pylori infec-
tion.
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